SEC Form 4																
FOF	UNIT	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549											OMB APPROVAL			
Section 16. Form 4 or Form 5 obligations may continue. See				AT OF CHANGES IN BENEFICIAL OWNE d pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940									stima	//B Number: 3235-0287 timated average burden urs per response: 0.5		
1. Name and Address of Reporting Person [*] DAVIS STEPHEN				2. Issuer Name and Ticker or Trading Symbol <u>ACADIA PHARMACEUTICALS INC</u> [ACAD]							5. Relationship of Reporting Person(s) to Issuer (Check all applicable) X Director 10% Owner					
(Last)(First)(Middle)C/O ACADIA PHARMACEUTICALS INC.12830 EL CAMINO REAL, SUITE 400				3. Date of Earliest Transaction (Month/Day/Year) 01/06/2023							X	X Officer (give title Other (specify below) CEO				
(Street) SAN DIEGO CA 92130			4. If Amendment, Date of Original Filed (Month/Day/Year)							6. Indiv Line) X	vidual or Joint/Group Filing (Check Applicable Form filed by One Reporting Person Form filed by More than One Reporting Person					
(Oity)	· · ·	(Zip) Table I - N	lon-Deriva	tive	Securities A	cquir	ed, C)isposed o	of, or E	Benef	icially	Owned				
1. Title of Security (Instr. 3) 2. Tra Date			2. Transaction	n ear)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8) Code V		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and Amount (A) or (D) Price				5. Amount of Securities Beneficially Owned Followi Reported Transaction(s) (Instr. 3 and 4)	Ĭ	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)	
Common Stock			01/06/2023			М		9,528	A		(1)	88,537		D		

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

3,904

D

\$17.1303(3)

84,633

D

s⁽²⁾

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				
Restricted Stock Units	(1)	01/06/2023		М			9,528	(4)	(4)	Common Stock	9,528	\$0.00	9,528	D	

Explanation of Responses:

Common Stock

1. Each restricted stock unit represents a contingent right to receive one share of Acadia common stock.

2. The sales reported in this Form 4 were made to cover the tax obligation that occurred upon the vesting of restricted stock units.

01/09/2023

3. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$17.13 to \$17.1939, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.

4. The restricted stock units vest in four equal annual installments beginning January 6, 2021.

Remarks:

/s/ Austin D. Kim, Attorney-in-01/10/2023

Fact

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

 * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.